Telesis Bio Inc EV / EBITDA
Was ist das EV / EBITDA von Telesis Bio Inc?
EV / EBITDA von Telesis Bio Inc ist N/A
Was ist die Definition von EV / EBITDA?
EV / EBITDA ist der Unternehmenswert geteilt durch das Einkommen vor Zinsen, Steuern, Abschreibungen und Amortisationen. Es ist ein Maß dafür, wie teuer eine Aktie ist und für Vergleiche zwischen Unternehmen häufiger gültig ist als das Preis-Gewinn-Verhältnis. Er misst den Preis (in Form des Unternehmenswerts), den ein Investor zu Gunsten des Cashflows des Unternehmens (in Form des EBITDA) bezahlt.
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV / EBITDA von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Telesis Bio Inc
Was macht Telesis Bio Inc?
sgi-dna, a wholly owned subsidiary of synthetic genomics inc., provides genomic solutions to advance scientific discovery. sgi-dna’s ever expanding suite of products, services, reagents, bioinformatics tools and instrumentation enables scientists to discover, design and build novel solutions for basic research, as well as for biomedical and industrial applications. sgi-dna’s genomic services include whole genome sequencing, dna synthesis, library design, bioinformatics, cell engineering, and plasmid dna cloning and purification. sgi-dna’s reagents include a complete suite of gibson assembly® and site directed mutagenesis kits as well as optimized cell lines such as vmax™ a novel, fast growing host system for molecular biology. to further enable synthetic biology workflows, sgi-dna offers the bioxp™ 3200 system. this fully automated genomics workstation allows the creation of double stranded dna fragments, automated cloning, as well as next generation sequencing dna library preparation.
Unternehmen mit ev / ebitda ähnlich Telesis Bio Inc
- Ximen Mining hat EV / EBITDA von N/A
- Rebel Capital 2.0 hat EV / EBITDA von N/A
- Hong Kong Johnson Hldg Co Ltd hat EV / EBITDA von N/A
- VOTI Detection hat EV / EBITDA von N/A
- Lift & Co hat EV / EBITDA von N/A
- Novatti hat EV / EBITDA von N/A
- Telesis Bio Inc hat EV / EBITDA von N/A
- In8 Bio hat EV / EBITDA von N/A
- Nitin Fire Protection Industries hat EV / EBITDA von N/A
- Renalytix AI plc hat EV / EBITDA von N/A
- Sunmirror Ag Sf 1 hat EV / EBITDA von N/A
- Sinotruk (Hong Kong) hat EV / EBITDA von N/A
- Cross River Ventures hat EV / EBITDA von N/A